פוסטר 100/6 - Foster 100/6
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||
|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | R03AK Adrenergics and other drugs for obstructive airway diseases | ||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||
| צ×רת ××ª× | ש×××¤× - INHALATION | ||||||
| צ×רת ××× ×× | PRESSURISED SOLUTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||
| ×ת×××× | Foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.COPD :Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. | ||||||
| |||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| פ×ס×ר 100/6 ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | CHIESI FARMACEUTICI S.P.A, ITALY |
| ×©× ××¢× ×ר×ש×× | KAMADA LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 8/2012. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | {{{ת×ר×× ×¢××××}}} |
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־13:02